OP0055 Sulfasalazine improves the number of flares of acute anterior uveitis over a one year period

Abstract

0-10). Utilities were measured with the EuroQoL (EQ-5D utility ) (range 0-1). A time-integrated summary score defined the clinical effects (BASFI-AUC) and utilities (EQ-5D utility -AUC) over time. Both direct (health care and non-health care) and indirect costs were included. Resource utilisation and absence from paid work were registered weekly by the patients in a diary. All costs were calculated from a societal perspective. Results 111 patients completed the diary (group 1 n = 38; group 2 n = 36; control group n = 37). The between-group difference (95% CI) for the BASFI-AUC was 1.0 (0.4 to 1.6; p = 0.001) for group 1 versus controls, and 0.6 (0.1 to 1.1; p = 0.020) for group 2 versus controls. The between-group difference for the EQ-5D utility -AUC was 0.17 (0.09 to 0.25; p < 0.001) for group 1 versus controls, and 0.08 (0.00 to 0.15; p = 0.04) for group 2 versus controls. The mean total costs per patient (including costs for spa therapy) during the study period were ?3023 for group 1, ?3240 for group 2, and ?1754 for the control group. The incremental cost-effectiveness ratio was ? 1269 per unit effect gained in functional ability for group 1, and ?2477 for group 2. The costs per QALY gained were ?7465 for group 1 and ?18575 for group 2. Conclusion Combined spa-exercise therapy is more effective and shows favourable cost-effectiveness and cost-utility ratios compared to weekly group physical therapy alone in patients with ankylosing spondylitis.

The effect of methotrexate and sulfasalazine on the course of HLA-B27-positive anterior uveitis: results from a retrospective cohort study

“…Our study is in line with previously published data on the effect of SSZ in AAU regarding reduction of severity and number of flares (20,21,27). We can now demonstrate a similar efficacy of MTX in reducing flare rate and, moreover, observe a beneficial effect in patients presenting with CME, a severe vision-threatening complication of AAU.…”

“…Sulfasalazine (Azulfidine, SSZ) is a classical DMARD that has been extensively studied and is often used for first-line medical treatment of rheumatoid arthritis (RA) and inflammatory bowel disease since its use was approved in the USA in 1950. SSZ has previously been suggested as potential treatment for AAU [21] and a reduction in flare rate and severity of AAU by this treatment has been described [20,21]. Sieper et al suggested a similar efficacy for SSZ and the TNF inhibitor etanercept in preventing uveitis relapses [27].…”

“…While extensively studied and well established for the treatment of many other uveitis entities, the effect of nonbiological DMARDs on the AAU course is still not well defined. For both SSZ and MTX, a reduction in the AAU flare rate has been reported [20][21][22], while studies directly comparing the efficacy of both medications are missing. In this retrospective case-control study, we therefore compared the effect of MTX and SSZ on the AAU course in HLA-B27positive patients.…”

Uveitis as an Open Window to Systemic Inflammatory Diseases

“…The type of maintenance therapy depends on the underlying rheumatic features. In patients with frequent recurrences (at least 2-3/year) and mild rheumatic manifestations, SSZ, which had been evaluated in a small study [93] and in a randomized trial including 22 patients [94], is an option [91]. An open clinical trial on 9 patients also suggested the efficacy of MTX at an initial dose of 7.5 to 20 mg/week to reduce the rate of recurrence of AU in patients who had more than 3 recurrences of AU in the past year [95].…”

Prevalencia y características de uveítis como manifestación extraarticular en Espondiloartritis Axial

“…En el caso de ataques recurrentes de uveítis, los antiinflamatorios no esteroideos (AINE) pueden aliviar los síntomas por un período corto 30 . Las DME convencionales como sulfasalazina (SSZ) y metotrexato (MTX) tienen una evidencia limitada en el tratamiento de esta manifestación [31][32][33][34][35] . En este estudio, si bien se observó significativamente mayor frecuencia de tratamiento con DME en los pacientes con UAA, no fue posible discriminar si la DME fue indicada como parte del tratamiento para el compromiso ocular o para alguna otra manifestación.…”